Early research (Phase 1)Ended earlyNCT05765734What this trial is testingTAS3351 in NSCLC Patients With EGFRmtWho this might be right forNon-Small Cell Lung Cancer Taiho Oncology, Inc. 18
Not applicableApproved For MarketingNCT01649284What this trial is testingAfatinib Expanded Access ProgramWho this might be right forCarcinoma, Non-Small-Cell Lung Boehringer Ingelheim
Testing effectiveness (Phase 2)UnknownNCT05519293What this trial is testingPhase I/IIa Study of H002 in NSCLC With Active EGFR MutationWho this might be right forNon-small Cell Lung Cancer RedCloud Bio 76
Large-scale testing (Phase 3)Active Not RecruitingNCT04035486What this trial is testingOsimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)Who this might be right forNon-Small Cell Lung Cancer AstraZeneca 587
Not applicableStudy completedNCT05862194What this trial is testingRetrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLCWho this might be right forNon-small Cell Lung Cancer Yuhan Corporation 534
Not applicableEnded earlyNCT02932345What this trial is testingGefitinib Long-term Survivor StudyWho this might be right forEGFR Mutation Positive Advanced Non-small-cell Lung Cancer AstraZeneca 59
Testing effectiveness (Phase 2)WithdrawnNCT03240393What this trial is testingStudy of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)Who this might be right forCarcinomaNon-Small-Cell Lung Cancer Novartis Pharmaceuticals
Not applicableActive Not RecruitingNCT05103605What this trial is testingProspective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR MutationsWho this might be right forNon Small Cell Lung Cancer AstraZeneca 274
Early research (Phase 1)Ended earlyNCT03711422What this trial is testingAfatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLCWho this might be right forNon-small Cell Lung CancerLeptomeningeal DiseaseCentral Nervous System Metastases National Cancer Centre, Singapore 2
Early research (Phase 1)Not Yet RecruitingNCT07461727What this trial is testingAn Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver MetastasesWho this might be right forNon-Small Cell Lung CancerMetastatic Non-small Cell Lung CancerLiver Metastases+2 more Cancer Institute and Hospital, Chinese Academy of Medical Sciences 15
Early research (Phase 1)Looking for participantsNCT06905197What this trial is testingA Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)Who this might be right forNon Small Cell Lung Cancer Dizal Pharmaceuticals 140
Testing effectiveness (Phase 2)UnknownNCT04358562What this trial is testingGefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With GefitinibWho this might be right forNon-small Cell Lung CancerEGFR Gene Mutation Second Affiliated Hospital of Nanchang University 240
Post-approval studies (Phase 4)UnknownNCT04401059What this trial is testingSynergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective StudyWho this might be right forCarcinomaNon-Small-Cell Lung CancerAdenocarcinoma Tian Xie 744
Testing effectiveness (Phase 2)Looking for participantsNCT07231068What this trial is testingA Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR MutationWho this might be right forNon-Small Cell Lung Cancer Henan Genuine Biotech Co., Ltd. 153
Testing effectiveness (Phase 2)Looking for participantsNCT05442060What this trial is testingTo Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer OBI Pharma, Inc 60
Large-scale testing (Phase 3)Study completedNCT02296125What this trial is testingAZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerWho this might be right forLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer AstraZeneca 674
Large-scale testing (Phase 3)UnknownNCT03849768What this trial is testingEvaluate Safety and Efficacy of HS-10296 as First-Line Treatment in PatientsWho this might be right forNon Small Cell Lung Cancer Jiangsu Hansoh Pharmaceutical Co., Ltd. 429
Testing effectiveness (Phase 2)Looking for participantsNCT07058519What this trial is testingOsimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLCWho this might be right forLocally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) Shanghai Chest Hospital 250
Not applicableStudy completedNCT03059641What this trial is testingTherapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in ChinaWho this might be right forLung NeoplasmsLung Cancer, Nonsmall CellAdenocarcinoma of Lung+1 more Geneplus-Beijing Co. Ltd. 300
Testing effectiveness (Phase 2)Looking for participantsNCT05579366What this trial is testingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Who this might be right forHigh Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more Genmab 884